Foundations acquire a critical new role as federal funding for cancer research falters

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The fight against cancer is complex. It’s global. And it’s indisputably expensive. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Ryan Schoenfeld, PhD
CEO, The Mark Foundation
Raymond N. DuBois, MD, PhD
Executive chair of the board, The Mark Foundation; Director, Medical University of South Carolina Hollings Cancer Center; Past dean of Medicine, the Medical University of South Carolina
Table of Contents

YOU MAY BE INTERESTED IN

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
Historically, the research initiatives of the Foundation for AIDS Research (amfAR) have focused on finding a cure for HIV. Four decades of HIV research have reshaped our understanding of the immune system, and insights from HIV have been leveraged in adjacent fields, including cancer immunology. Innovation can be bi-directional and reciprocal. Seminal findings in cancer immunology have also furthered understanding of HIV biology. 
Ryan Schoenfeld, PhD
CEO, The Mark Foundation
Raymond N. DuBois, MD, PhD
Executive chair of the board, The Mark Foundation; Director, Medical University of South Carolina Hollings Cancer Center; Past dean of Medicine, the Medical University of South Carolina

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login